Set Name side by side		Hit Count	Set Name result set
DB=US	SPT,PGPB; PLUR=YES; OP=ADJ		
<u>L7</u>	(c5 or c5a)same (antibod\$) and (treat\$ or therap\$ or prevent\$ or inhibit\$ or suppress\$ or antagoni\$)same (joint\$ or arthritis)same (c5a or c5)	39	<u>L7</u>
<u>L6</u>	(c5 or c5a)same (antibod\$) and (treat\$ or therap\$ or prevetn\$ or inhibit\$ or suppress\$ or antagoni\$)same (joint\$ or arthritis)	301	<u>L6</u>
<u>L5</u>	(c5 or c5a)same (antibod\$) same (joint\$ or arthritis)	19	<u>L5</u>
<u>L4</u>	(c5 or c5a)same (antibod\$) and (joint\$ or arthritis)	339	<u>L4</u>
<u>L3</u>	(L1 or L2) and (complement of c5 or c5a)	4	<u>L3</u>
<u>L2</u>	matis-louis\$	5	<u>L2</u>
<u>L1</u>	wang-yi\$	321	<u>L1</u>

END OF SEARCH HISTORY

Term	Documents
C5	38820
C5S	18
C5A	1365
C5AS	1
JOINT	517394
JOINTS	190785
ARTHRITIS	50961
ARTHRITI	4
ANTIBOD\$	0
ANTIBOD	808
ANTIBODANTIBODA	1
((C5 OR C5A) SAME (ANTIBOD\$) AND (TREAT\$ OR THERAP\$	
OR INHIBITS OR SUPPRESSS OR PREVENTS OR BLOCKS OR	48
ANTAGONI\$)SAME(JOINT OR ARTHRITIS)SAME (C5 OR	
C5A)).USPT,PGPB,JPAB,EPAB,DWPI.	

There are more results than shown above. Click here to view the entire set.

Previous Page Next Page

Generate Collection	Print

### Search Results - Record(s) 11 through 20 of 48 returned.

Scarch Results - Record(s) 11 tillough 20 of 40 fetathed.
☐ 11. <u>6566343</u> . 03 Jan 02; 20 May 03. High affinity nucleic acid ligands of complement system proteins. Biesecker; Gregory, et al. 514/44; 435/235.1 435/243 435/325 435/366 436/501 536/23.1. A61K031/70 C07H021/04 C12N007/00 C12N001/20 C12N015/00.
☐ 12. <u>6465614</u> . 21 Jul 99; 15 Oct 02. High-affinity response-selective C-terminal analogs of C5a anaphylatoxin. Sanderson; Sam D., et al. 530/328; 424/185.1 530/324 530/325 530/326 530/327. A61K038/00 C07K005/00 C07K007/00.
☐ 13. <u>6395888</u> . 29 Sep 98; 28 May 02. High affinity nucleic acid ligands of complement system proteins. Biesecker; Gregory, et al. 536/23.1; 435/6 536/22.1. C07H021/02 C07H021/04 C12Q001/68.
14. <u>6355245</u> . 07 Jun 95; 12 Mar 02. <u>C5</u> -specific <u>antibodies</u> for the treatment of inflammatory diseases. Evans; Mark J., et al. 424/145.1; 424/130.1 424/133.1 424/135.1 424/139.1 424/141.1 424/158.1 435/326 435/328 435/331 435/332 435/337 435/343 435/346 530/387.1 530/387.3 530/387.9 530/388.1 530/388.23 530/388.25 530/388.7. A61K039/395 C07K016/36 C12N005/12.
15. 6333034. 24 Aug 98; 25 Dec 01. Process for inhibiting complement activation via the alternative pathway. Gupta-Bansal; Rekha, et al. 424/139.1; 424/130.1 514/8. A61K039/395 A61K038/17.
☐ 16. 6328968. 11 Jun 99; 11 Dec 01. Methods and means for modifying complement activation. Van Lier; Rene Antonius Wilhelmus, et al. 424/184.1; 514/12. A61K038/36 A61K038/17.
☐ 17. 6297024. 05 Feb 99; 02 Oct 01. Methods for assessing complement activation. Hugli; Tony E., et al. 435/23; 435/24 435/4. C12Q001/37 C12Q001/00.
☐ 18. 6255059. 17 Jan 96; 03 Jul 01. Methods for identifying G protein coupled receptor effectors. Klein; Christine A., et al. 435/7.31; 435/254.2 435/254.21 435/6 435/69.1 435/69.7 435/7.2 530/300 530/350 536/23.4 536/23.5. C12N005/10 C12N015/11 C12Q001/68 G01N033/566.
19. 6235494. 08 Feb 99; 22 May 01. Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates. Hugli; Tony E 435/24; 435/4 435/968 435/975 530/300. C12Q001/37 C12Q001/00.
☐ 20. <u>6180355</u> . 07 May 99; 30 Jan 01. Method for diagnosing and treating chronic pelvic pain syndrome. Alexander; Richard B., et al. 435/7.1; 435/7.8. G01N033/50 G01N033/53.
Generate Collection Print

Term	Documents
C5	38820
C5S	18
C5A	1365
C5AS	1
JOINT	517394
JOINTS	190785
ARTHRITIS	50961
ARTHRITI	4
ANTIBOD\$	0
ANTIBOD	808
ANTIBODANTIBODA	1
((C5 OR C5A) SAME (ANTIBOD\$) AND (TREAT\$ OR THERAP\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR BLOCK\$ OR ANTAGONI\$)SAME(JOINT OR ARTHRITIS)SAME (C5 OR C5A)).USPT,PGPB,JPAB,EPAB,DWPI.	48

There are more results than shown above. Click here to view the entire set.

<u>Previous Page</u> <u>Next Page</u>

Generate Collection Print

# Search Results - Record(s) 21 through 30 of 48 returned.

☐ 21. 6159705. 24 Sep 97; 12 Dec 00. Recombinant yeast cells for identifying receptor effectors. Trueheart; Joshua, et al. 435/29; 435/254.11. C12N001/19 C12Q001/02.
☐ 22. <u>6140490</u> . 12 Feb 98; 31 Oct 00. High affinity nucleic acid ligands of complement system proteins. Biesecker; Gregory, et al. 536/24.31; 435/6 435/91.2 536/23.1 536/25.4. C07H021/04 C12Q001/68 C12P019/34.
☐ 23. 6100042. 13 Oct 94; 08 Aug 00. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor. Fowlkes; Dana Merriman, et al. 435/7.1; 435/252.3 435/483 435/6. C12Q001/68 G01N033/53.
☐ 24. <u>5942599</u> . 04 Dec 97; 24 Aug 99. High-affinity response-selective C-terminal analogs of C5a anaphylatoxin. Sanderson; Sam D., et al. 530/328;. A61K038/00 A61K038/02 C07K005/00 C07K007/00.
25. <u>5876951</u> . 05 Jun 95; 02 Mar 99. Yeast cells engineered to produce pheromone system protein surrogates and uses therefor. Fowlkes; Dana M., et al. 435/7.31; 435/254.11 435/254.2 435/254.21. G01N033/53.
☐ 26. <u>5861272</u> . 02 Jun 95; 19 Jan 99. C5A receptor. Li; Yi, et al. 435/69.1; 435/320.1 536/23.5. C12P021/02 C12N015/85.
☐ 27. <u>5851528</u> . 03 Jul 97; 22 Dec 98. Methods of inhibiting complement activation. Ko; Jone-Long, et al. 424/185.1; 424/192.1 514/12 530/350 530/380. A61K038/16 C07K014/46.
☐ 28. <u>5837499</u> . 05 Jun 95; 17 Nov 98. DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same. van Oostrum; Jan, et al. 435/69.6; 435/252.3 435/252.33 435/254.11 435/320.1 435/325 435/69.7 435/70.1 435/71.1 530/408 536/23.4 536/23.5. C12P021/00 C07K014/435 C12N015/12.
☐ 29. <u>5808109</u> . 07 Jun 95; 15 Sep 98. Compounds that inhibit complement and/or suppress immune activity. Sindelar; Robert D., et al. 549/345;. C07D307/94.
☐ 30. <u>5807824</u> . 05 Jun 95; 15 Sep 98. C5A receptor antagonists having substantially no agonist activity. van Oostrum; Jan, et al. 514/12; 530/324. A61K038/00 A61K038/16.
Generate Collection Print

Term	Documents
C5	38820
C5S	18
C5A.	1365
C5AS	1
JOINT	517394
JOINTS	190785
ARTHRITIS	50961
ARTHRITI	4
ANTIBOD\$	0
ANTIBOD	808
ANTIBODANTIBODA	1
((C5 OR C5A) SAME (ANTIBOD\$) AND (TREAT\$ OR THERAP\$	
OR INHIBITS OR SUPPRESSS OR PREVENTS OR BLOCKS OR	48
ANTAGONI\$)SAME(JOINT OR ARTHRITIS)SAME (C5 OR	, ,
C5A)).USPT,PGPB,JPAB,EPAB,DWPI.	

There are more results than shown above. Click here to view the entire set.

Previous Page Next Page

Set Name	e Query e	Hit Count S	et Name result set	
DB=U	SPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
<u>L2</u>	(c5 or c5a) same (antibod\$) and (treat\$ or therap\$ or inhibit\$ or suppress\$ or prevent\$ or block\$ or antagoni\$)same(joint or arthritis)same (c5 or c5a)	48	<u>L2</u> ·	
<u>L1</u>	(c5 or c5a) same (antibod\$) and (treat\$ or therap\$ or inhibit\$ or suppress\$ or prevent\$ or block\$ or antagoni\$)same(joint or arthritis)	315	<u>L1</u>	

END OF SEARCH HISTORY

Generate Collection Print

## Search Results - Record(s) 1 through 10 of 48 returned.

☑ 1. <u>20030129187</u> . 17 Aug 02. 10 Jul 03. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b. Fung, Michael, et al. 424/144.1; 424/141.1 435/334 530/388.15 530/388.22 A61K039/395 C12N005/06 C07K016/28.
2. <u>20030078221</u> . 03 Jan 02. 24 Apr 03. High affinity nucleic acid ligands of complement system proteins. Biesecker, Gregory, et al. 514/44; 435/6 435/91.2 536/23.5 C12Q001/68 A61K048/00 C07H021/04 C12P019/34.
☐ 3. <u>20030054402</u> . 13 Sep 01. 20 Mar 03. Methods and compositions for identifying receptor effectors. Klein, Christine A., et al. 435/7.1; 435/325 435/7.2 G01N033/53 G01N033/567 C12N005/02.
4. <u>20030027245</u> . 05 Jun 95. 06 Feb 03. HUMAN G-PROTEIN COUPLED RECEPTOR. LI, YI, et al. 435/69.1; 435/320.1 435/325 530/350 536/23.2 536/23.5 C07K014/705 C12P021/02 C12N005/06 C07H021/04.
5. 20030022310. 30 Sep 02. 30 Jan 03. Human G-protein coupled receptor. Li, Yi, et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C12P021/02 C12N005/06 C07K014/705 C07H021/04.
6. 20030013161 . 15 Aug 02. 16 Jan 03. C5a receptor. Li, Yi, et al. 435/69.1; 435/320.1 435/325 435/6 530/350 536/23.5 C07K014/705 C12Q001/68 C07H021/04 C12P021/02 C12N005/06.
7. 20030008380. 10 May 99. 09 Jan 03. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor. FOWLKES, DANA MERRIMAN, et al. 435/254.2; 435/7.31 G01N033/53 G01N033/569 C12N001/14 C12N001/16 C12N001/18.
8. 20020015957. 30 Apr 01. 07 Feb 02. Diagnostics and therapeutics for macular degeneration-related disorders. Hageman, Gregory S., et al. 435/6; 351/200 C12Q001/68 A61B003/00.
9. 20010036650. 31 May 01:01 Nov 01. C5a receptor. Li, Yi, et al. 435/69.1; 435/325 530/350 536/23.5 C12P021/02 C12N005/06 C07H021/04 C07K014/705.
☐ 10. <u>20010026926</u> . 21 Dec 00. 04 Oct 01. Methods and compositions for identifying receptor effectors. Klein, Christine A., et al. 435/7.31; 435/254.2 435/325 G01N033/569 C12N001/16 C12N005/06.
Generate Collection Print

7/24/03 11:02 AM

Generate Collection

L5: Entry 13 of 19

File: USPT


Nov 17, 1998

DOCUMENT-IDENTIFIER: US 5837499 A

TITLE: DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same

#### Brief Summary Text (7):

Complement is beneficial when directed against an appropriate target such as invading microorganisms or tumor cells, but has clear pathogenic potential if activated inappropriately. For instance, the anaphylatoxins, e.g., C5a, have been implicated as causative or aggravating factors in the pathogenesis of several inflammatory diseases such as adult respiratory distress syndrome and rheumatoid <a href="arthritis">arthritis</a>. Bautsch et al., Biochem. J. 288:261-266 (1992); Haslett et al., J. Immunol. 142:3510-3517 (1989). In particular, the aberrant presence of C5a in tissue has been detected in patients afflicted with rheumatoid <a href="arthritis">arthritis</a>, osteoarthritis, psoriasis and noncardiac pulmonary edema. C5a has been found to be a principal inflammatory mediator produced by complement activation by virtue of additional activities that include recruitment and stimulation of inflammatory leukocytes and augmentation of <a href="antibody production">antibody production</a>. See Mollison et al., Proc. Natl. Acad. Sci. USA 86:292-296 (1989).




### Search Results -

Term	Documents
C5	28681
C5S	16
C5A	1240
C5AS	1
ARTHRITIS	30404
ARTHRITI	1
ANTIBOD\$	0
ANTIBOD	800
ANTIBODAY	1
ANTIBODEES	2
ANTIBODEIES	1
((C5 OR C5A)SAME (ANTIBOD\$) AND (TREAT\$ OR THERAP\$ OR PREVENT\$ OR INHIBIT\$ OR SUPPRESS\$ OR ANTAGONI\$)SAME (JOINT\$ OR ARTHRITIS)SAME (C5A OR C5)).USPT,PGPB.	39

There are more results than shown above. Click here to view the entire set.

Control of the Contro	Search History
	Clear Clear
Search:	L7 Refine Search
Database:	US Patents Full-Text Database US Pre-Grant Publication Full-Text Database  JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins  ▼

DATE: Thursday, July 24, 2003 Printable Copy Create Case



### Search Results -

Term	Documents
C5 .	38820
C5S	18
C5A	1365
C5AS	1
JOINT .	517394
JOINTS	190785
ARTHRITIS	50961
ARTHRITI	4
ANTIBOD\$	0
ANTIBOD	808
ANTIBODANTIBODA	1
((C5 OR C5A) SAME (ANTIBOD\$) AND (TREAT\$ OR THERAP\$ OR INHIBIT\$ OR SUPPRESS\$ OR PREVENT\$ OR BLOCK\$ OR ANTAGONI\$)SAME(JOINT OR ARTHRITIS)SAME (C5 OR C5A)).USPT,PGPB,JPAB,EPAB,DWPI.	48

There are more results than shown above. Click here to view the entire set.

Database:	US Patents Full-Text Database US Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwant World Patents Index IBM Technical Disclosure Bulletins
Search:	L2 Refine Search  Recall Text  ← Clear
Search History	

DATE: Thursday, July 24, 2003 Printable Copy Create Case